Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1791-1800 Newer>

BusinessWeek February 28, 2005 Capell & Carey	A Drug Watchdog To Rival The FDA Europe's agency will soon have new powers. Will it take the lead on safety?
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool February 18, 2005 John Bluis	Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises.
The Motley Fool February 18, 2005 Charly Travers	A Drug to Get Your Blood Pumping Encysive's Thelin combines low risk with high sales potential.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix?
BusinessWeek February 28, 2005 Amy Barrett	Pfizer Is "At a Fork in the Road" CEO Henry McKinnell discusses the drugmaker's outlook, from new products and advertising to the challenges facing health care.
BusinessWeek February 28, 2005 David Kiley	The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders.
BusinessWeek February 28, 2005 Gene G. Marcial	J&J May Pump Up Animas Animas, a little-known maker of small glucose pumps, could take a big share of the insulin-measurement market.
The Motley Fool February 17, 2005 Stephen D. Simpson	More Work to Do at Gentiva The country's largest home health-care provider has ample room to improve operating efficiency. Although Gentiva shouldn't be expected to post breathtaking growth, the valuation on these shares looks interesting.
<Older 1791-1800 Newer> Return to current articles.